To investigate the usefulness of the plasma big endothelin-1 (big ET-1) level in predicting the severity of new-onset stable angiography-proven coronary artery disease (CAD). Methods: A total of 963 consecutive stable CAD patients with more than 50% stenosis in at least one main vessel were enrolled. The patients were classified into the three groups according to the tertile of the Gensini score (GS, low GS 20, n 300; intermediate GS 20-40, n 356 and high GS 40, n 307), and the relationship between the big ET-1 level and GS was evaluated. Results: The plasma levels of big ET-1 increased significantly in association with increases in the GS tertile (p 0.007). A multivariate analysis suggested that the plasma big ET-1 level was an independent predictor for a high GS (OR 2.26, 95%CI: 1.23-4.15, p 0.009) , and there was a positive correlation between the big ET-1 level and the GS (r 0.20, p 0.000). The area under the receiver operating characteristic curve (AUC) for the big ET-1 level in predicting a high GS was 0.64 (95%  CI 0.60-0.68, p 0.000), and the optimal cutoff value for the plasma big ET-1 level for predicting a  high GS was 0.34 fmol/mL, with a sensitivity of 62.6% and specificity of 60.3%. In the high- big ET-1 level group (≥ 0.34 fmol/mL), there were significantly increased rates of three-vessel disease (43.6% vs. 35.4%, p 0.017) and a high GS [31 (17-54) vs. 24 (16-44), p 0.001] compared with that observed in the low-big ET-1 level group. Conclusions: The present findings indicate that the plasma big ET-1 level is a useful predictor of the severity of new-onset stable CAD associated with significant stenosis. J Atheroscler Thromb, 2015; 22:126-135.
Introduction
Coronary artery disease (CAD) is recognized as a health threat worldwide and remains a leading cause of both morbidity and mortality 1) . Hence, understanding its predictors would greatly aid in disease prevention and treatment, and the possible relationships between various plasma markers and CAD have intensively been investigated [2] [3] [4] [5] .
Among these markers, endothelin 1 (ET-1) has been demonstrated to play a role in endothelial dysfunction and inflammation 6) , both of which are actively involved in the pathophysiology of the onset and progression of CAD, from the formation of atherosclerotic plaque to the development of acute coronary syndrome (ACS) and heart failure following myocardial infarction 7) . Moreover, it has been reported that the baseline plasma ET-1 level can be used to predict the short-or long-term outcomes in patients with ACS and/or acute heart failure [8] [9] [10] [11] .
However, most previous studies have paid more attention to the usefulness of measuring the plasma ET-1 levels in patients with unstable CAD 8) . Furthermore, in addition to the lack of evidence regarding the and/or triglyceride (TG) level of ≥ 150 mg/dL.
Laboratory Tests
All baseline laboratory data were derived from venous blood samples obtained after a 12-hour overnight fast prior to coronary angiography. All biomarkers were analyzed according to standard hematological and biochemical tests based on our previous study 4) . The plasma big ET-1 level was measured using a highly sensitive and specific commercial sandwich enzyme immunoassay (BI-20082H, Biomedica, Wien, Austria). Each blood sample was immediately placed on ice and then centrifuged for 20 minutes at 4 . Plasma separation was subsequently performed at 4 , and the sample was stored at 80 . All samples were analyzed in duplicate, and the mean value was used for the analysis. Biotinylated anti-big ET-1 antibodies were raised with 100% reactivity to big ET-1 and less than 1% reactivity to ET-1. The levels of high-sensitivity C-reactive protein (hs-CRP) were determined using immunoturbidimetry (Beckmann Assay 360, Bera, California, USA), as previously reported 14) .
Angiographic Examinations
Selective coronary angiography was performed in all enrolled individuals, and the results were analyzed by at least two interventional physicians. The definition of CAD included obstructive stenosis reaching or more than 50% of the vessel lumen diameter in any of the main coronary arteries, including the left main coronary artery (LM), left anterior descending artery (LAD), left circumflex coronary artery (LCX), right coronary artery (RCA) and/or main branch of the vasculature.
The severity of CAD was determined according to a GS assessment system in which the degree of stenosis was given 1 point for 25% stenosis, 2 points for 26% to 50% stenosis, 4 points for 51% to 75% stenosis, 8 points for 76% to 90% stenosis and 32 points for total occlusion. Each score was then multiplied by a factor representing the importance of the lesion's position in the coronary artery system; for example, 5 for the LM, 2.5 for the proximal LAD or proximal LCX, 1.5 for the mid-region and 1 for the distal LAD 15) .
The enrolled patients were classified into the three groups based on the tertile of the GS (low GS 20-point, n 300; intermediate GS 20-40 points, n 356; high GS 40-point, n 307).
Statistical Analysis
All analyses were performed using the SPSS version 19.0. software program (Chicago, Illinois, USA). relationship between the plasma ET-1 level and the severity of stable CAD, no data supporting this association using strict assessments, such as the Gensini score (GS) assessment system, are currently available, especially in the Chinese population. More importantly, no studies focusing on the diagnostic value of the plasma ET-1 level for discriminating the severity of CAD have been conducted. Finally, because ET-1 has a short half-life in blood, as it is rapidly taken up in the pulmonary vasculature, the plasma ET-1 levels may be grossly underestimated 12, 13) . Recently, big ET-1, the biological precursor of ET-1 with a longer half-life, has been reported to be a more accurate indicator of the degree of activation of the endothelial system. Therefore, the present study explored the usefulness of the plasma big ET-1 level in predicting the severity of new-onset stable CAD in a Chinese cohort treated at a single center.
Design and Methods

Study Population
The study protocol complied with the Declaration of Helsinki and was approved by our hospital ethics review board (Fu Wai Hospital & National Center for Cardiovascular Diseases, Beijing, China). Written informed consent was obtained from all patients enrolled in this analysis.
A total of 963 patients with chronic stable angina (typical exertional chest pain exhibiting the same pattern for ≥ 3 months) were selected from among 2,025 consecutive patients who underwent diagnostic coronary angiography and were confirmed to have stenosis of not less than 50% in at least one main coronary vessel at the Division of Dyslipidemia of Fu Wai Hospital between April 2011 and March 2014. Patients with a history of pre-percutaneous coronary intervention (Pre-PCI, n 600), pre-coronary artery bypass grafting (pre-CABG, n 69), post-myocardial infarction without revascularization (n 355), an abnormal baseline cardiac troponin I level (cTnI, n 26) or valvular heart disease (n 12) were excluded from this study. The clinical characteristics, lipid profiles, laboratory data and medications of the enrolled patients were collected.
Hypertension was defined as a repeated blood pressure of ≥ 140/90 mm Hg (at least two times in different environments) or the use of antihypertensive drugs. Diabetes mellitus (DM) was defined as a fasting serum glucose level of ≥ 6.99 mmol/L on multiple occasions or the use of treatment with insulin or oral hypoglycemic agents. Hyperlipidemia was defined as a fasting total cholesterol (TC) level of ≥ 200 mg/dL ET-1 and hs-CRP values). The variables were compared using either Student's t -test or an analysis of variance (ANOVA) (normal distribution) or the Mann-Whitney U -test or Kruskal-Wallis test (abnormal distribution). Categorical variables were summarized as
The Kolmogorov-Smirnov test was used to test the distribution pattern. Continuous variables were presented as the mean standard deviation (SD) (normal distribution) or median with 25th and 75th percentiles (abnormal distribution, including the GS, big The data are presented as the mean SD, median (Q1-Q3 quartiles) or number (%), as appropriate. Abbreviations: GS Gensini score; BMI body mass index; DM diabetes mellitus; PVD peripheral vascular disease; TC total cholesterol; LDL-C low-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; AST aspartate aminotransferase; ALT alanine aminotransferase; ALP alkaline phosphatase; HbA1c glycosylated hemoglobin A1C; NT-pro-BNP N-terminal pro-brain natriuretic peptide; LVFE left ventricular ejection fraction; hs-CRP high-sensitivity C-reactive protein; ET-1 endothelin-1; fmol/mL femtomole per milliliter; CCB calcium channel blocker; ACE-I angiotensin-converting enzyme inhibitor. p-value obtained from an analysis of variance, the Kruskal-Wallis test or the chi-squared test.
(71.4%) and 275 women (28.6%) with 22-82 (mean: 58.73 9.49) years of age. The baseline data of the enrolled subjects were summarized according to the tertile of the GS (low GS group, n 300, 31.2%; intermediate GS group, n 356, 37.0%; high GS group, n 307, 32.0%). The median GS was 28 (16-50) points, with a range from 2 to 194 points. The characteristics of each patient group are shown in Table 1 . In brief, the patients with higher GS values more frequently exhibited lower high-density lipoprotein cholesterol (HDL-C), apolipoprotein A (apoA) and left ventricular ejection fraction (LVEF) values and higher low-density lipoprotein cholesterol (LDL-C), apoB, creatinine, alanine aminotransferase (ALT) and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) values. Importantly, the big ET-1 levels were significantly higher in the group with a high GS than in the group with a low GS (p 0.01; Table 1 and Fig. 1) .
frequencies with percentages and were compared using the chi-square test.
In order to identify factors independently associated with a high GS (above 40 points), binary univariate and multiple logistic regression analyses were performed using a forward stepwise selection process. Variables with a p-value of 0.05 in the univariate logistic regression analysis were included in the multivariate logistic regression analysis. The relationships between the variables and the GS values were assessed using a Spearman correlation analysis. A receiver operating characteristic (ROC) curve analysis was carried out in order to document the predictive power of the plasma big ET-1 level for identifying a high GS. A p-value of less than 0.05 was considered to be statistically significant.
Results
Baseline Characteristics
The study population consisted of 688 men ET-1 endothelin-1; GS Gensini score. The levels of big ET-1 are presented as the median with 25th and 75th percentiles. p-value a p-value for trend; p-value b p-value for a high GS ( 40) versus a non-high GS.
p-value a =0.007, p-value b =0.002
Correlation and ROC Curve Analyses
According to the Spearman correlation analysis, there was a definitively positive correlation between the plasma big ET-1 level and the GS (r 0.20, p 0.001; Fig. 2) . Moreover, in the ROC curve analysis, the area under the curve (AUC) for the plasma big ET-1 level indicated a strong discriminatory power (AUC 0.64, 95% CI: 0.60-0.68, and p 0.001) for predicting a high GS ( 40, Fig. 3) , and the optimal cutoff value of the plasma big ET-1 level for predicting a high GS was 0.34 fmol/mL, with a sensitivity of
Logistic Regression Analysis
Following the univariate logistic regression analysis, gender, DM, LVEF, NT-pro-BNP, creatinine and big ET-1 were entered into the multivariate logistic regression analysis based on having a p-value of 0.05. As indicated in Table 2 , after adjusting for gender, age, DM, current smoking, hypertension, hyperlipidemia, family history of CAD, LVEF and creatinine, the big ET-1 level was demonstrated to be an independent predictor of the severity of CAD (OR 2.26, 95% CI 1.23-4.15, and p 0.009; Table 2 ). ET-1 endothelin-1. The correlations between the variables were examined using a Spearman correlation analysis.
r=0.204 p<0.001
CAD patients (OR 2.26, 95% CI 1.23-4.15, and p 0.009); (2) the ROC curve analysis showed that the optimal cutoff value of the plasma big ET-1 level for predicting a high GS was 0.34 fmol/mL, with a sensitivity of 62.6% and specificity of 60.3%. An impaired endothelial cell function, particularly the vasomotor dysfunction, is an early component of the development of atherosclerosis 16) , and endothelial dysfunction is characterized by the impairment of endothelium-dependent vasodilatation, which has been linked to all known atherogenic risk factors, including DM, hypertension, dyslipidemia and cigarette smoking 17, 18) . Moreover, it has been demonstrated that the presence of endothelial dysfunction is an independent risk factor for future cardiovascular events in patients with CAD 19) , and a number of recent studies have shown that the severity of endothelial dysfunction both strongly correlates with the development of CAD and predicts the incidence of future cardiovascular events 7, 9, 10) .
ET-1 is a potent endothelium-derived vasoconstrictor that is known to play an important role in the pathogenesis of CAD 20) The blood flow appears to be the most important physiological stimulus regulating ET-1 synthesis and release; in short, a decreased blood flow resulting from artery stenosis increases the pro-62.6% and specificity of 60.3%. The number of diseased vessels and GS were also compared between the two groups according the optimal cutoff value of the big ET-1 level (low group 0.34 fmol/mL, n 461 and high group ≥ 0.34 fmol/mL, n 502). Consequently, in group with a high big ET-1 level, there was a significantly higher rate of three-vessel disease and a lower rate of one-vessel disease compared with that observed in the low big ET-1 level group (43.6% vs. 35.4%, p 0.017 and 20.9% vs. 29.3%, p 0.003, respectively). Moreover, the GS values were significantly higher in the group with a high big ET-1 level than that in the group with a low big ET-1 level [31 vs. 24 , p 0.001; Table 3 and Fig. 4 ].
Discussion
To our knowledge, there are no previous studies regarding the predictive value of the big ET-1 level in patients with new-onset stable CAD. The present study, therefore, provides novel information with respect to the usefulness of the big ET-1 level in predicting the severity of stable CAD. The main findings of this study are as follows: (1) the baseline plasma big ET-1 level was found to be an independent predictor of a high GS ( 40 points) in the new-onset stable is why we chose to assess exertional angina pectoris patients with significant coronary artery stenosis (at least one main vessel with stenosis of not less than duction and release of ET-1 7) . Meanwhile, the ET-1 level may remain elevated for substantially longer periods in patients with continuing ischemia 13, 21) , which * # study, the mean level of plasma big ET-1 in the newonset stable CAD patients was 0.35 (0.25-0.51) fmol/ mL. The current study, therefore, comfirmed the value of big ET-1 for detecting high-risk subjects from among new-onset stable CAD patients and firstly showed the optimal cutoff value of the big ET-1 level for detecting severe patients with CAD (0.34 fmol/ mL). It is also worth mentioning that the severity of CAD was assessed using both the GS system and the number of diseased vessels in the present study. Furthermore, according to the correlation analyses, there was a definitively positive correlation between the plasma big ET-1 level and the GS (r 0.20, p 0.000).
As is well known, the GS assessment system 15) is a simple and widely used tool for evaluating the severity of coronary stenosis. For this reason, we chose the GS as a parameter for evaluating the severity of CAD in this Chinese cohort study. Accordingly, based on the relatively large sample size and strict enrollment criteria using a widely recognized coronary assessment system, our data comfirmed and extended the findings of previous studies with regard to the usefulness of measuring the plasma ET-1 level in patients with stable CAD. For example, patients with clinically suspected CAD who exhibit a high plasma big ET-1 level may be at high risk. Such patients should undergo coronary angiography in order to confirm the diagnosis, and the detection of a high big ET-1 level should be taken into consideration when selecting the therapeutic strategy.
In conclusion, the present data demonstrated that the plasma big ET-1 level was a valuable independent predictor of the severity of new-onset stable CAD, as assessed by the GS, and that a big ET-1 level of ≥ 0.34 fmol/mL might indicate the presence of severe lesions in patients with stable CAD.
